Biologic agents and the therapy of chronic spontaneous urticaria
- 1 August 2014
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Allergy and Clinical Immunology
- Vol. 14 (4), 347-353
- https://doi.org/10.1097/aci.0000000000000083
Abstract
Chronic spontaneous urticaria (CSU) has been traditionally managed with antihistamines. Over the years, studies using different formulations and dosing regimens have delineated the limits of their effectiveness, thus emphasizing the need for alternative therapeutic approaches. Data keep accumulating that the monoclonal anti-immunoglobulin E antibody omalizumab, until recently reserved for the treatment of severe atopic asthma, may have a beneficial therapeutic and safety profile for CSU cases resistant to the effect of antihistamines. Since the beginning of 2013, a host of studies have been published paving the way for licensing of omalizumab for the treatment of CSU. Dose-finding studies have indicated 300 mg monthly as a possible optimal treatment regimen. Efficacy proving randomized controlled trials were further supported by open-label studies confirming its effectiveness in real life. One report has been published so far presenting positive data about the use of another biologic agent, rituximab, depleting the blood stream of B cells, in patients with CSU. New convincing evidence in support of the efficacy and safety of omalizumab in the treatment of CSU has accumulated over the past year, providing another tool for coping with the antihistamine-resistant cases.Keywords
This publication has 41 references indexed in Scilit:
- Retrospective analysis of the efficacy of omalizumab in chronic refractory urticariaAllergy and Asthma Proceedings, 2013
- Omalizumab in chronic urticaria: a retrospective series of 15 casesDermatologic Therapy, 2013
- Omalizumab and hypersensitivity reactionsCurrent Opinion in Allergy and Clinical Immunology, 2013
- A Long Term Case Series Study of the Effect of Omalizumab on Chronic Spontaneous UrticariaAnnals of Dermatology, 2013
- Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide PerspectiveWorld Allergy Organization Journal, 2012
- Omalizumab in chronic urticariaCurrent Opinion in Allergy and Clinical Immunology, 2012
- A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 2011
- Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidaseJournal of Allergy and Clinical Immunology, 2011
- Low‐dose and short‐term cyclosporine treatment in patients with chronic idiopathic urticaria: A clinical and immunological evaluationThe Journal of Dermatology, 2008
- Cyclosporine in chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trialJournal of the American Academy of Dermatology, 2006